TEL AVIV, Israel- Therapix Biosciences Ltd. (Nasdaq: TRPX) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, provides updates and dates in connection with the previous announcement made by Therapix Biosciences Ltd. (“Therapix” or the “Company”) regarding the Company’s intention to voluntarily delist its ordinary shares, NIS 0.1 par value each (the “Shares”) solely from the Tel Aviv Stock Exchange Ltd. (“TASE”), the Company hereby updates the following:
In coordination with the TASE, the Shares will be delisted from the TASE on August 9, 2018 (“Delisting Date”), and until the Delisting Date, Therapix’s Shares will continue to be traded on the TASE. The last trading day in which the Shares are to be traded on TASE will be August 7, 2018.
The Company’s American Depositary Shares (“ADSs”), each representing forty (40) of the Company’s Shares, shall continue to be traded on the Nasdaq Capital Market (the “Nasdaq”).
Shareholders who are interested in continuing to hold or trade the Company’s Shares on the Nasdaq should notify their bank or broker as soon as possible and request to convert their Shares to ADSs.
The Company will bear the costs and commissions associated with the conversion of the Shares to ADSs charged by the banks and brokers for all shareholders who convert their Shares on or before August 7, 2018. Every forty (40) Shares shall be converted to one (1) ADS.
The Company urges all holders of Shares that are traded on the TASE to convert their Shares into ADSs at the earliest.
Holders of the Company’s Shares are encouraged to contact their banks or brokers as soon as possible with any questions about the conversion process.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Because such statements deal with future events and are based on Therapix’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Therapix could differ materially from those described in or implied by the statements in this press release. For example, forward-looking statements include statements regarding the Company’s plans with respect to its clinical trials and its intent to report material developments and information regarding such trials. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Therapix Biosciences Ltd.’s Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) on April 30, 2018 and in subsequent filings with the SEC. Except as otherwise required by law, Therapix disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Australia says no further Facebook, Google amendments as final vote nears
By Colin Packham
CANBERRA (Reuters) – Australia will not alter legislation that would make Facebook and Alphabet Inc’s Google pay news outlets for content, a senior lawmaker said on Monday, as Canberra neared a final vote on whether to pass the bill into law.
Australia and the tech giants have been in a stand-off over the legislation widely seen as setting a global precedent.
Other countries including Canada and Britain have already expressed interest in taking some sort of similar action.
Facebook has protested the laws. Last week it blocked all news content and several state government and emergency department accounts, in a jolt to the global news industry, which has already seen its business model upended by the titans of the technological revolution.
Talks between Australia and Facebook over the weekend yielded no breakthrough.
As Australia’s senate began debating the legislation, the country’s most senior lawmaker in the upper house said there would be no further amendments.
“The bill as it stands … meets the right balance,” Simon Birmingham, Australia’s Minister for Finance, told Australian Broadcasting Corp Radio.
The bill in its present form ensures “Australian-generated news content by Australian-generated news organisations can and should be paid for and done so in a fair and legitimate way”.
The laws would give the government the right to appoint an arbitrator to set content licencing fees if private negotiations fail.
While both Google and Facebook have campaigned against the laws, Google last week inked deals with top Australian outlets, including a global deal with Rupert Murdoch’s News Corp.
“There’s no reason Facebook can’t do and achieve what Google already has,” Birmingham added.
A Facebook representative declined to comment on Monday on the legislation, which passed the lower house last week and has majority support in the Senate.
A final vote after the so-called third reading of the bill is expected on Tuesday.
Lobby group DIGI, which represents Facebook, Google and other online platforms like Twitter Inc, meanwhile said on Monday that its members had agreed to adopt an industry-wide code of practice to reduce the spread of misinformation online.
Under the voluntary code, they commit to identifying and stopping unidentified accounts, or “bots”, disseminating content; informing users of the origins of content; and publishing an annual transparency report, among other measures.
(Reporting by Byron Kaye and Colin Packham; Editing by Sam Holmes and Hugh Lawson)
GSK and Sanofi start with new COVID-19 vaccine study after setback
By Pushkala Aripaka and Matthias Blamont
(Reuters) – GlaxoSmithKline and Sanofi on Monday said they had started a new clinical trial of their protein-based COVID-19 vaccine candidate, reviving their efforts against the pandemic after a setback in December delayed the shot’s launch.
The British and French drugmakers aim to reach final testing in the second quarter, and if the results are conclusive, hope to see the vaccine approved by the fourth quarter after having initially targeted the first half of this year.
In December, the two groups stunned investors when they said their vaccine would be delayed towards the end of 2021 after clinical trials showed an insufficient immune response in older people.
Disappointing results were probably caused by an inadequate concentration of the antigen used in the vaccine, Sanofi and GSK said, adding that Sanofi has also started work against new coronavirus variants to help plan their next steps.
Global coronavirus infections have exceeded 110 million as highly transmissible variants of the virus are prompting vaccine developers and governments to tweak their testing and immunisation strategies.
GSK and Sanofi’s vaccine candidate uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines. It will be coupled with an adjuvant, a substance that acts as a booster to the shot, made by GSK.
“Over the past few weeks, our teams have worked to refine the antigen formulation of our recombinant-protein vaccine,” Thomas Triomphe, executive vice president and head of Sanofi Pasteur, said in a statement.
The new mid-stage trial will evaluate the safety, tolerability and immune response of the vaccine in 720 healthy adults across the United States, Honduras and Panama and test two injections given 21 days apart.
Sanofi and GSK have secured deals to supply their vaccine to the European Union, Britain, Canada and the United States. It also plans to provide shots to the World Health Organization’s COVAX programme.
To appease critics after the delay, Sanofi said earlier this year it had agreed to fill and pack millions of doses of the Pfizer/BioNTech vaccine from July.
Sanofi is also working with Translate Bio on another COVID-19 vaccine candidate based on mRNA technology.
(Reporting by Pushkala Aripaka in Bengaluru and Matthias Blamont in Paris; editing by Jason Neely and Barbara Lewis)
Don’t ignore “lockdown fatigue”, UK watchdog tells finance bosses
By Huw Jones
LONDON (Reuters) – Staff at financial firms in Britain are suffering from “lockdown fatigue” and their bosses are not always making sure all employees can speak up freely about their problems, the Financial Conduct Authority said on Monday.
Many staff at financial companies have been working from home since Britain went into its first lockdown in March last year to fight the COVID-19 pandemic.
One year on, the challenges have evolved from adapting to working remotely to dealing with mental health issues, said David Blunt, the FCA’s head of conduct specialists.
“During this third lockdown, there has been a greater impact on mental well-being, with many people struggling with job security, caring responsibilities, home schooling, bereavements and lockdown fatigue.”
Bosses should continually revisit how they lead remote teams, he said.
“The impact of COVID-19 is creating a huge workload for those considered to be high performers, while the remote environment potentially makes it much more challenging for those who were previously considered low performers to change that perception,” Blunt told a City & Financial online event.
Companies should consider “psychological safety” or ensuring that all employees feel confident about speaking out and challenging opinions.
“We’ve heard varying reports of how successful this has been,” Blunt said.
Pressures in the financial sector were highlighted this month when accountants KPMG said its UK chairman Bill Michael had stepped aside during a probe into comments he made to staff.
The Financial Times said Michael, who later apologised for his comments, had told staff to “stop moaning” about the impact of the pandemic on their work lives.
Blunt was speaking as the FCA next month completes the full rollout of rules that force senior managers at financial firms to be personally accountable for their decisions to improve conduct standards.
There have only been a “modest” number of breaches reported to regulators so far as firms worry about being “tainted” but more cases will become public as sanctions are revealed, Blunt said.
“Regulators won’t be impressed by lowballing the figures.”
(Reporting by Huw Jones; Editing by Mark Heinrich)
Report explores the Ceramic Ink Market likely to emerge over a period of 2019– 2029
Ceramic Ink market players – Torrecid Group, Ferro Corporation, Marabu GmbH & Co. KG, Chromaline, Fenzi Group SpA, Rex-Tone Industries...
Detailed examination of the Micro Robots Market to hold a high potential for growth by 2021
Micro Robots market study depicts an extensive analysis of all the players running in the Micro Robots Market report based on distribution...
Dredging Market Research Report by Type, by Production Technology, by Application, by Function – Global Forecast to 2030 – Cumulative Impact of COVID-19
A recent market study published by FMI on the Dredging Market includes global industry analysis for 2015-2019 & opportunity assessment for 2020-2030,...
Synthetic Leather Market 2021 Segmentation and Analysis by Recent Trends, consumption by Regional data, Development, Investigation, Growth by to 2027
Synthetic Leather Market – Global Industry Analysis and Opportunity Assessment 2016–2026 This report by Future Market Insights on the global synthetic...
Automotive Steering System Market In-Depth Analysis on Size, Cost Structure and Prominent Key Players -JTEKT Corporation, Nexteer Automotive Group Ltd., Showa Corporation
FMI offers a 10-year forecast for the Automotive Steering System between 2017 and 2027. In terms of value, the market is expected...
Coating Additives Market Size, Top Key Players, Latest Trends, Regional Insights and Global Industry Dynamics By 2022
Coating additives are emerging as a convenient and effective option for improving performance in terms of anti-corrosion, anti-microbial, self-cleaning, and...
Automotive Tire Market In-Depth Analysis, Growth Strategies and Comprehensive Forecast to 2027
The exhaustive research report titled “Automotive Tire Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027)” gives all the guidelines essential to...
Unexpected Growth Seen for Paint Additives Market by 2022 | Akzo Nobel NV, Arkema SA, Ashland Global Holdings, Inc
Future Market Insights (FMI) has offered a 5-year forecast for the global paint additives market in its new report titled...
Polymer Coated Fabrics Market Research Development, Top Companies, Trends And Growth 2017 To 2022 | BASF SE, Akzo Nobel NV, Saint-Gobain, PPG Industries, Inc
A new market study on polymer coated fabrics, published by Future Market Insights, reveals the changing demands for technical textiles...
Industrial Vacuum Cleaners Market Research Development, Top Companies, Trends And Growth 2018 To 2028 | Alfred Kärcher GmbH & Co. KG, American Vacuum Company, Nilfisk Group
This FMI study offers a ten-year analysis and forecast for the global Industrial Vacuum Cleaners market for the period between 2018 and...